Bristol-Myers Squibb Advances Leadership Position in Immuno-Oncology
The impact of comorbidity and stage on prognosis of Danish melanoma patients, 1987–2009: a registry-based cohort study
‘Truly Remarkable’ Response with Combination for Melanoma ‘Truly Remarkable’ Response with Combination for Melanoma
Melanoma Treatment Harnesses Immune System to Combat Cancer Cells
Bristol melanoma drug combo marks new advance in immunotherapy
Advances in the Systemic Treatment of Metastatic Melanoma
Integrated Proteomics Pipeline Yields Novel Biomarkers for Predicting Preeclampsia [Preeclampsia]
T cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patients
MIA promotes melanoma development through activation of YBX1.
The mouse ruby-eye 2(d) (ru2(d) /Hps5(ru2-d) ) allele inhibits eumelanin but not pheomelanin synthesis.